To include your compound in the COVID-19 Resource Center, submit it here.

OncoMed raises $55M in follow-on

Cancer stem cell company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) raised $55 million through the sale

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE